Literature DB >> 22415316

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

Daniel Gorovets1, Kasthuri Kannan, Ronglai Shen, Edward R Kastenhuber, Nasrin Islamdoust, Carl Campos, Elena Pentsova, Adriana Heguy, Suresh C Jhanwar, Ingo K Mellinghoff, Timothy A Chan, Jason T Huse.   

Abstract

PURPOSE: Diffuse gliomas represent the most prevalent class of primary brain tumor. Despite significant recent advances in the understanding of glioblastoma [World Health Organization (WHO) IV], its most malignant subtype, lower grade (WHO II and III) glioma variants remain comparatively understudied, especially in light of their notable clinical heterogeneity. Accordingly, we sought to identify and characterize clinically relevant molecular subclasses of lower grade diffuse astrocytic gliomas. EXPERIMENTAL
DESIGN: We conducted multidimensional molecular profiling, including global transcriptional analysis, on 101 lower grade diffuse astrocytic gliomas collected at our own institution and validated our findings using publically available gene expression and copy number data from large independent patient cohorts.
RESULTS: We found that IDH mutational status delineated molecularly and clinically distinct glioma subsets, with IDH mutant (IDH mt) tumors exhibiting TP53 mutations, platelet-derived growth factor receptor (PDGFR)A overexpression, and prolonged survival, and IDH wild-type (IDH wt) tumors exhibiting EGFR amplification, PTEN loss, and unfavorable disease outcome. Furthermore, global expression profiling revealed three robust molecular subclasses within lower grade diffuse astrocytic gliomas, two of which were predominantly IDH mt and one almost entirely IDH wt. IDH mt subclasses were distinguished from each other on the basis of TP53 mutations, DNA copy number abnormalities, and links to distinct stages of neurogenesis in the subventricular zone. This latter finding implicates discrete pools of neuroglial progenitors as cells of origin for the different subclasses of IDH mt tumors.
CONCLUSION: We have elucidated molecularly distinct subclasses of lower grade diffuse astrocytic glioma that dictate clinical behavior and show fundamental associations with both IDH mutational status and neuroglial developmental stage. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22415316     DOI: 10.1158/1078-0432.CCR-11-2977

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  63 in total

Review 1.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

2.  Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.

Authors:  Hussein A Abbas; Ngoc Hoang Bao Bui; Kimal Rajapakshe; Justin Wong; Preethi Gunaratne; Kenneth Y Tsai; Cristian Coarfa; Elsa R Flores
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

3.  Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E.

Authors:  Ying Zhang; Stefan Pusch; James Innes; Kastytis Sidlauskas; Matthew Ellis; Joanne Lau; Tedani El-Hassan; Natasha Aley; Francesca Launchbury; Angela Richard-Loendt; Jasper deBoer; Sheng Chen; Lei Wang; Andreas von Deimling; Ningning Li; Sebastian Brandner
Journal:  Cancer Res       Date:  2019-08-07       Impact factor: 12.701

4.  Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas".

Authors:  Robert B Jenkins
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

5.  Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.

Authors:  Kaishi Satomi; Makoto Ohno; Yuko Matsushita; Masamichi Takahashi; Yasuji Miyakita; Yoshitaka Narita; Koichi Ichimura; Akihiko Yoshida
Journal:  Mod Pathol       Date:  2020-10-19       Impact factor: 7.842

6.  How molecular testing can help (and hurt) in the workup of gliomas.

Authors:  Kenneth Clark; Zoya Voronovich; Craig Horbinski
Journal:  Am J Clin Pathol       Date:  2013-03       Impact factor: 2.493

7.  Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients.

Authors:  Fausto J Rodriguez; Tarik Tihan; Doris Lin; William McDonald; Janice Nigro; Burt Feuerstein; Sadhana Jackson; Kenneth Cohen; Peter C Burger
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

8.  TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.

Authors:  Ze-Lin Sun; Aden Ka-Yin Chan; Ling-Chao Chen; Chao Tang; Zhen-Yu Zhang; Xiao-Jie Ding; Yang Wang; Chong-Ran Sun; Ho-Keung Ng; Yu Yao; Liang-Fu Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas.

Authors:  Sriram Venneti; Michelle Madden Felicella; Thomas Coyne; Joanna J Phillips; Daniel Gorovets; Jason T Huse; Julia Kofler; Chao Lu; Tarik Tihan; Lisa M Sullivan; Mariarita Santi; Alexander R Judkins; Arie Perry; Craig B Thompson
Journal:  J Neuropathol Exp Neurol       Date:  2013-04       Impact factor: 3.685

10.  Targeting cancer metabolism.

Authors:  Beverly A Teicher; W Marston Linehan; Lee J Helman
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.